Pancreatic Cancer Research

ResearcherTokyo University of Pharmacy and Life SciencesActive in the last 2 years

Kiyoko Fukami

ORCID-verified (high confidence)As of 13 November 2026

Matched on ORCID iD 0000-0003-3205-1542; OpenAlex author ID A5105409269.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers
2 (first author 0, last author 2)
Pancreatic cancer trials
0
Pancreatic cancer grants
0
Labs led
1
Collaborators
1
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 2

  1. Zic family member 5 promotes RIO kinase 3 expression to enhance pancreatic cancer survival. Last author DOI 10.1111/febs.70125↗
  2. Zic family member 5 promotes survival in human pancreatic cancer and cholangiocarcinoma cells. Last author DOI 10.1016/j.bbrep.2022.101289↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

  1. Reiko Satow · 2 shared papers, 2022–2025

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.